Supernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.15, Zacks reports. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Stock Up 0.4 %

SUPN traded up $0.13 on Tuesday, hitting $32.81. 961,698 shares of the company traded hands, compared to its average volume of 458,164. Supernus Pharmaceuticals has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a 50 day moving average of $37.41 and a 200-day moving average of $35.39. The stock has a market capitalization of $1.81 billion, a PE ratio of 30.66 and a beta of 0.90.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $57.00 to $36.00 in a research note on Wednesday, February 19th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.